Search clinical trials for: anti-CD19/20-CAR vector-transduced T cells

Total 480 results

Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
University of Colorado, Denver

Recruiting

UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Acute Lymphoblastic Leukemia | Acute Lymphoid Leukemia

United States
Dr. Melody Smith, MD, MS
Orca Biosystems, Inc.

Recruiting

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Lymphoid Leukemia

United States
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Southwest Hospital, China

Unknown

the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)

Lymphoma, Large B-Cell, Diffuse

China
Miltenyi Biomedicine GmbH

Recruiting

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia Recurrent | Chronic Lymphocytic Leukemia Recurrent | Chronic Lymphocytic Leukemia Refractory

Germany
Southwest Hospital, China

Unknown

A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

Malignant Glioma of Brain | Gastric Carcinoma | Colorectal Carcinoma

China
Miltenyi Biomedicine GmbH

Not yet recruiting

MB-CART19.1 in Refractory SLE

SLE - Systemic Lupus Erythematosus

Germany
Affiliated Hospital to Academy of Military Medical...

Unknown

Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies

Lymphoma | Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies

Lymphoma | Leukemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma

Non-hodgkin Lymphoma,B Cell

China
Southwest Hospital, China

Unknown

A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies

Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia | Multiple Myeloma

China
Southwest Hospital, China

Unknown

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Lymphoma | Leukemia

China
Southwest Hospital, China

Unknown

A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies

Myeloid Malignancies

China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Hepatocellular Carcinoma | Non-small Cell Lung Cancer | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Shenzhen Institute for Innovation and Translational...
Dongguan People's Hospital

Completed

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Guangzhou Medical...
Guangzhou First People's Hospital; First People's Hospital of Foshan; Dongguan... and other collaborators

Unknown

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma,B Cell

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Vasculitis | Amyloidosis | Autoimmune Hemolytic Anemia | POEMS Syndrome

China
KK Women's and Children's Hospital
Singapore General Hospital

Recruiting

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Lymphoblastic Leukemia | Lymphoblastic Leukemia, Acute Adult | Lymphoblastic Leukemia in Children | CAR | B-cell Acute Lymphoblastic Leukemia | Large B-cell Lymphoma

Singapore
The Children's Hospital of Zhejiang University...
Chongqing Precision Biotech Co., Ltd

Recruiting

Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Children With Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus | CAR-T Cell Therapy

China
Xinqiao Hospital of Chongqing
Xuzhou Medical University

Unknown

Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients (MendCART)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Stage III/IV Adult Diffuse Large Cell Lymphoma | Stage III/IV Follicular Lymphoma | Stage III/IV Mantle Cell Lymphoma

China
University College, London
Deutsche Krebshilfe e.V., Bonn (Germany); European Union; The Leukemia and Lymphoma... and other collaborators

Terminated

CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) (CD19TPALL)

Acute Lymphoblastic Leukemia

United Kingdom, Germany
Peking Union Medical College Hospital
Cellular Biomedicine Group Ltd.

Completed

A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects

B-cell Non-Hodgkin Lymphoma

China
Seattle Children's Hospital

Active, not recruiting

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

CD 19+ Acute Leukemia

United States
Yan'an Affiliated Hospital of Kunming Medical University
KAEDI

Unknown

CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases

Autoimmune Diseases

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Completed

Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
University College, London

Enrolling by invitation

A New Study Evaluating the Activity of Modular CAR T for mYeloma (MCARTY)

Multiple Myeloma

United Kingdom
Liqun Zou

Recruiting

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Leukemia

China
Yan'an Affiliated Hospital of Kunming Medical University

Recruiting

Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia

B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Not yet recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Beijing GoBroad Hospital

Recruiting

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

Acute Lymphoblastic Leukemia, in Relapse | B-cell Acute Lymphoblastic Leukemia | Refractory Acute Lymphoid Leukemia

China
University of Pennsylvania

Terminated

CD19 Redirected Autologous T Cells for Hodgkin Lymphoma

Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Anhui Provincial Hospital

Recruiting

CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies

CAR

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Relapse | CD19 Positive | Refractory

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

B-cell Acute Lymphocytic Leukemia

China
Sheba Medical Center

Unknown

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Acute Lymphoblastic Leukemia, B-precursor | Non-Hodgkin Lymphoma, B-cell

Israel
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China

Search clinical trials for: anti-CD19/20-CAR vector-transduced T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations